scholarly article | Q13442814 |
P50 | author | Rosario Yerbes | Q39031881 |
Abelardo López-Rivas | Q39031948 | ||
Adriana Eramo | Q39906067 | ||
Ruggero De Maria | Q64679020 | ||
P2093 | author name string | Gustavo Ortiz-Ferrón | |
Ana I López-Pérez | |||
P2860 | cites work | Inhibition of death receptor signals by cellular FLIP | Q24316446 |
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members | Q24337108 | ||
Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL | Q24554360 | ||
Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts | Q24793079 | ||
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol | Q24805832 | ||
Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli | Q28116145 | ||
TRAIL receptor-2 signals apoptosis through FADD and caspase-8 | Q28142998 | ||
Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex | Q28209029 | ||
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors | Q28245164 | ||
Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1 | Q28256819 | ||
Death receptors: signaling and modulation | Q28280897 | ||
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2 | Q28609079 | ||
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy | Q30586812 | ||
Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5. | Q31120918 | ||
Safety and antitumor activity of recombinant soluble Apo2 ligand | Q33855449 | ||
Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo | Q34082542 | ||
Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. | Q34438239 | ||
Potential and caveats of TRAIL in cancer therapy | Q34625563 | ||
Cyclin-dependent kinase inhibitors | Q35193645 | ||
Promoting apoptosis as a strategy for cancer drug discovery | Q36292878 | ||
Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms | Q36529789 | ||
E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis | Q36565534 | ||
An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis | Q38290395 | ||
Direct repression of the Mcl-1 promoter by E2F1. | Q38291801 | ||
NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling | Q39459534 | ||
c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis | Q39644966 | ||
Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation | Q39895438 | ||
Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. | Q40227228 | ||
Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells | Q40236310 | ||
Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis | Q40316401 | ||
Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. | Q40384718 | ||
E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short). | Q40391790 | ||
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells | Q40414448 | ||
Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail | Q40424237 | ||
Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. | Q40448034 | ||
Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. | Q40479108 | ||
Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells | Q40504942 | ||
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. | Q40554408 | ||
Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. | Q40560316 | ||
Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. | Q40599197 | ||
Myeloid cell factor-1 is a critical survival factor for multiple myeloma | Q40655990 | ||
Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing | Q40674172 | ||
Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases | Q40791420 | ||
Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development | Q40868554 | ||
Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines | Q40871201 | ||
Role of acidic sphingomyelinase in Fas/CD95-mediated cell death. | Q41725574 | ||
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. | Q41747264 | ||
Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. | Q42099676 | ||
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway | Q42832237 | ||
Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells | Q43722451 | ||
Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. | Q44165080 | ||
Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway | Q44389071 | ||
Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling | Q44550507 | ||
Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation | Q44905141 | ||
A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. | Q45251395 | ||
Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts | Q46383982 | ||
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. | Q48965240 | ||
Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. | Q51028667 | ||
MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. | Q53398443 | ||
The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels. | Q53988288 | ||
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) | Q78516462 | ||
Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis | Q82096730 | ||
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma | Q83919556 | ||
P433 | issue | 6 | |
P921 | main subject | pleiotropy | Q1134884 |
apoptotic process | Q14599311 | ||
P304 | page(s) | 664-676 | |
P577 | publication date | 2008-06-01 | |
P1433 | published in | Cell Research | Q1524018 |
P1476 | title | Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism | |
P478 | volume | 18 |